The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Agreed, the special divi does not get included in the annual (normal) divi. Have a look at last years end of year results pres which mentions divi of 4p for the year but doesn't include the special from earlier in the year.
Quite a good set of results given the terrible macro picture around the world. I'm going to see this with a cup more than half full and point out that if they can still make a profit and pay a good divi with metal prices this low and a recession over the horizon then this is a good set of assets. They seem to be suffering minimal inflation pressures/increases in AISC etc too.
A positive RNS filled with promise. 'a few weeks' I would imagine means before the end of October at the latest? That they can do all this in the teeth of the current macro environment is impressive. It underlines the value of the asset.
Can I ask you where you met them HighlyGeared? This is one group of Execs that I might actually want to see in person.
I much prefer the quiet cerebral types who know what they're doing and don't over promise. These two are clearly capable business men and I feel confident my investment is being looked after. The alternative to this is a combination of style, flash, smoke and mirrors and we can all name a few of those. Also, if you're in this for the long term, then you don't want the CEO/CFO to be too integral to the company's success, so that if they leave, the whole thing doesn't collapse.
A little collection of research for those new to TRX, looking forward to the results on Wednesday and wondering whether to buy in or not!
TRX: a reopening play, focussing on elective surgery, poised for growth.
Tissue Regenix is a pioneering medical devices company focussing on regenerative products. Having spent over £100 million researching, developing and gaining approval for a range of products in the USA and Europe, TRX has just completed an expansion programme which will enable the company to increase sales and revenue, just as elective surgery is resuming post-pandemic. This programme was completed on time and on budget and triples the capacity for processing and storage tissue. This increased supply, dovetailed with the return of elective surgery should lead to an increase in the company’s value.
TRX is one of the very companies with the necessary permissions and abilities to source tissue for wound repair in surgery. The industry has huge barriers to entry and is very highly regulated. This provides it with a moat to prevent competitors gaining a foothold.
Led by a new(ish) CEO and CFO TRX is determined to commercialise it’s products. With a clear path forwards for growth the team are building on an existing set of strategic agreements to increase the uptake for TRX’s product range. With an increasing number of new white label and distribution agreements already in place, and the promise of more to come, TRX is moving in the right direction.
FAQ
So, if it’s that good, why are the shares trading at less than a penny?
TRX got caught up in the collapse of the Woodford fund and suffered when this collapsed. A fundraise by the company which followed pushed the sp lower still. Since then though there is a new team in place and funding is much more secure than it was.
Does it have enough cash to survive?
Like many biotech firms cashflow is important at the pre profit stage. TRX is no exception but the company is funded for at least the 18 months and has come successfully through the pandemic maintaining sales from 2019-20. Now elective surgery has resumed, cash flow will rapidly increase. Remember, the vast majority of surgeries can only be delayed, they can’t be cancelled indefinitely which gives TRX a solid market for it’s products.
What kind of market are we talking about?
Although based in Yorkshire (God’s own country) the company’s sales are predominately in the US but some UK sales also take place and there has been recent progress in making further agreements in Europe, most recently in Poland.
Video of 2020 results from CEO and CFO
https://www.youtube.com/watch?v=VURo1glkV50
Hardman reports
https://www.hardmanandco.com/research/
Search on ‘linkedin’ for ‘Tissue Regenix’ for regular case studies by surgeons using TRX’s products and their feedback.
See this write up from a doctor/investor who did some serious research:
https://www.reddit.com/user/Jessie1991a/comments/krab7q/jessies_first_write_up
All looking good, worth having a nosey at the presentation to see the photos and understand the scale behind what these mines are going to look like!
I remember Larry saying once that deals tend to be weighted to the second half of the year. Don’t ask me for the reference/source though!
Positive news this morning. Another bit of good news flow and definitely a ‘hold’ for me.
There is competition, lots, but it doesn’t seem to be slowing TRX down. If you want a gander have a look:
https://www.woundsource.com/product-category/cellular-andor-tissue-based-products/non-viable-cells-tissue-based-human
This website is like the Amazon shop for surgeons. No prices unfortunately although I’m tempted to ask… DermaPure is on that page about half way down.
19th Sep according to dividendmax, usually fairly reliable site.
https://www.dividendmax.com/united-kingdom/london-stock-exchange/mining/atalaya-mining-plc/dividends
Certainly to have as much as possible in terms of manufacturing, vanadium supply etc coming from the US makes sense in light of the Inflation reduction act which seems to be a climate change ad stimulus package rolled into one. A climate change bill has been on the cards for a while now and it’s possible, indeed quite likely IMO, that IES have been aiming in this direction for some time and it’s mere serendipity that the recent focus on the US and this bill arrived at the same time. Unless Larry has fingers in pies we don’t know about?? Either way, there’s nothing like a macro trend, massive govt funding and a Californian CEO to help this along. California is one of the greenest regions on Earth and also one of the world’s largest economies. A 24% bounce today is heading in the right direction.
More irons in the fire for IES. And this will appeal far more state side than it does here which is all to the good given the new listing. The share price does not currently reflect the work the company is doing and the connections they are building. But it will in time.